Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

USP10 deubiquitinates FLT3. 2 / 2

1 | 1

➶

ubibrowser

"USP10, a primary cytoplasmic DUB, acts as an oncogene or a tumor suppressor by regulating various protein substrates, including FLT3, p53, AMPK, PTEN, etc."

30319415

➶

reach

"However, in acute myeloid leukemia (AML) patients with activating mutations in FMS‐like tyrosine kinase 3 (FLT3), USP10 deubiquitinates and stabilizes FLT3 by removing the proteolytic polyubiquitin chains and preventing FLT3 degradation, to aggravate tumor progress (Weisberg et al., 2017)."

31721429

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...